神经内分泌肿瘤分子影像与诊疗一体化共识
欧洲核医学协会Focus 3通过多学科Delphi流程就分化良好的神经内分泌肿瘤分子影像与放射性核素治疗达成共识,推荐[68Ga]Ga-DOTA-SSA PET/CT联合诊断性CT或MRI用于原发灶不明、转移性、分期/再分期及疑似肾上腺外嗜铬细胞瘤/副神经节瘤,[18F]FDG PET/CT用于神经内分泌癌、G3 NET及病灶不匹配的G1-2 NET,PRRT推荐用于胃肠道NET二线治疗等。
要点
- 疑似或已知NET行[68Ga]Ga-DOTA-SSA PET/CT时应联合诊断性CT或MRI。
- [18F]FDG PET/CT用于神经内分泌癌、G3 NET及CT阳性而[68Ga]Ga-DOTA-SSA阴性的G1-2 NET。
- PRRT推荐用于所有病灶均有[68Ga]Ga-DOTA-SSA摄取的胃肠道NET二线治疗。
诊断标准与关键数值
- [68Ga]Ga-DOTA-SSA PET/CT联合诊断性CT或MRI适用于原发灶不明NET检测、转移性NET、NET分期/再分期、疑似肾上腺外嗜铬细胞瘤/副神经节瘤及疑似副神经节瘤。
- [18F]FDG PET/CT适用于神经内分泌癌、G3 NET及CT阳性而[68Ga]Ga-DOTA-SSA阴性的病灶不匹配G1-2 NET。
- PRRT推荐用于所有病灶均有[68Ga]Ga-DOTA-SSA摄取的胃肠道NET二线治疗、疾病进展的G1/G2 NET,以及所有病灶在[18F]FDG和[68Ga]Ga-DOTA-SSA均阳性的部分G3 NET。
- 治疗完成后疾病稳定至少1年的患者可考虑PRRT再治疗。
临床应用与阅片要点
- 对原发灶不明、转移性或需分期/再分期的NET,阅片时应结合[68Ga]Ga-DOTA-SSA PET/CT与诊断性CT或MRI。
- 对神经内分泌癌、G3 NET及CT阳性而[68Ga]Ga-DOTA-SSA阴性的不匹配病灶,应加做[18F]FDG PET/CT。
- PRRT前需确认所有病灶均有[68Ga]Ga-DOTA-SSA摄取,G3 NET还需所有病灶在[18F]FDG和[68Ga]Ga-DOTA-SSA均阳性。
局限性
- NET为罕见且异质性疾病,难以获得强临床证据。
- 各国诊断和治疗选择的可及性不同,许多问题仍存争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). European Association of Nuclear Medicine (EANM) Focus 3 performed a multidisciplinary Delphi process to deliver a balanced perspective on molecular imaging and radionuclide therapy in well-differentiated neuroendocrine tumours (NETs). NETs form in cells that interact with the nervous system or in glands that produce hormones. These cells, called neuroendocrine cells, can be found throughout the body, but NETs are most often found in the abdomen, especially in the gastrointestinal tract. These tumours may also be found in the lungs, pancreas and adrenal glands. In addition to being rare, NETs are also complex and may be difficult to diagnose. Most NETs are non-functioning; however, a minority present with symptoms related to hypersecretion of bioactive compounds. NETs often do not cause symptoms early in the disease process. When diagnosed, substantial number of patients are already found to have metastatic disease. Several societies' guidelines address Neuroendocrine neoplasms (NENs) management; however, many issues are still debated, due to both the difficulty in acquiring strong clinical evidence in a rare and heterogeneous disease and the different availability of diagnostic and therapeutic options across countries. EANM Focus 3 reached consensus on employing 68gallium-labelled somatostatin analogue ([68Ga]Ga-DOTA-SSA)-based PET/CT with diagnostic CT or magnetic resonance imaging (MRI) for unknown primary NET detection, metastatic NET, NET staging/restaging, suspected extra-adrenal pheochromocytoma/paraganglioma and suspected paraganglioma. Consensus was reached on employing 18fluorine-fluoro-2-deoxyglucose ([18F]FDG) PET/CT in neuroendocrine carcinoma, G3 NET and in G1-2 NET with mismatched lesions (CT-positive/[68Ga]Ga-DOTA-SSA-negative). Peptide receptor radionuclide therapy (PRRT) was recommended for second line treatment for gastrointestinal NET with [68Ga]Ga-DOTA-SSA uptake in all lesions, in G1/G2 NET at disease progression, and in a subset of G3 NET provided all lesions are positive at [18F]FDG and [68Ga]Ga-DOTA-SSA. PRRT rechallenge may be used for in patients with stable disease for at least 1 year after therapy completion. An international consensus is not only a prelude to a more standardised management across countries but also serves as a guide for the direction to follow when designing new research studies.
引用
- Ambrosini V, Kunikowska J, Baudin E, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021. PMID: 33588146. doi:10.1016/j.ejca.2021.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。